UK cost agency says "no" to pricey Vertex cystic fibrosis drug

March 23, 2016 12:01 AM

38 0

LONDON, March 23 A new cystic fibrosis treatment from Vertex Pharmaceuticals has been rejected as too expensive by Britain's healthcare cost agency NICE.

The National Institute for Health and Care Excellence (NICE) said on Wednesday that Orkambi, priced at an annual 104,000 pounds ($149,000) per patient, was not a cost-effective use of state healthcare resources, even though it offers clinical benefits.

Read more

To category page